At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 292 enrolled

Drug / intervention

nivolumab +4 morebiological

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03338790

NCT03338790Phase 2Completed

Compare CT.gov

A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer

Bristol-Myers Squibb·interventional·Posted Nov 9, 2017·Updated Jan 27, 2026

In Brief

A Phase 2 clinical trial evaluating nivolumab, docetaxel, and 3 other interventions for Prostate Cancer. Completed, enrolled 292 participants across 66 sites in 11 countries.

Detailed Summary

The purpose of this study is to assess safety and efficacy of nivolumab in combination with rucaparib, docetaxel, or enzalutamide in participants with castration-resistant prostate cancer that has spread.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsProstate Cancer

CountriesArgentina, Australia, Brazil, Canada, Chile, Colombia, France, Germany, Mexico, Spain, United States

CollaboratorsClovis Oncology, Inc., Astellas Pharma Inc

Timeline

Phase 2CompletedFinished

201820192020202120222023202420252026

First PostedNov 2017

Enrollment StartDec 2017

Primary CompletionJan 2021

Study CompletionJan 2025

TodayJul 2026

First PostedNov 9, 2017

Enrollment StartDec 19, 2017

Primary CompletionJan 13, 2021

Study CompletionJan 10, 2025

TodayJul 2, 2026

Enrollment to primary: 3.1 yearsPosted 8.6 years ago